home / case-based-peer-perspectives / first-line-treatment-for-egfr-mutated-advanced-metastatic-non-small-cell-lung-cancer-a-47-year ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

What are the toxicity differences you encounter when using i.e. combination ami+laz, chemotherapyosi+ctx? Please discuss your proactive AE management strategies. Ami/Laz: How does recent data from ...

Rezivertinib outperforms gefitinib as first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.